海辰药业 (300584.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

35.4x

Market Cap

CNY 3.94B

MomentumView details →

1D Return

−0.33%

YTD Return

−39.05%

RSI (14)

38.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

35.4x

Market Cap

CNY 3.94B

RSI (14)

38.3

MomentumView details →

1D Return

−0.33%

YTD Return

−39.05%

ProfitabilityView details →

Gross Margin

80.82%

Net Margin

6.44%

EBITDA Margin

16.03%

ROE (TTM)

4.15%

ROA (TTM)

2.90%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

+26.97%

EPS YoY

+5.95%

FCF YoY

—

Revenue CAGR 3Y

+8.42%

EPS CAGR 3Y

+9.03%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.24x

Current Ratio

1.07x

Quick Ratio

0.83x

Div Yield

0.33%

Div Rate

CNY 0.10

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

688.74M

Net Income (TTM)

44.38M

Op. CF (TTM)

45.54M

Latest newsMore news →

Haishen Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 32.065 million yuan, up 9.97% year-on-year.12d ago

Similar companies

银宝山新002786.SZ 申昊科技300853.SZ ST龙大002726.SZ 森远股份300210.SZ 大地海洋301068.SZ 宝莱特300246.SZ Find similar companies →

Latest newsMore news →

Haishen Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 32.065 million yuan, up 9.97% year-on-year.12d ago